Compare · DXR vs MDLN
DXR vs MDLN
Side-by-side comparison of Daxor Corporation (DXR) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXR and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $44.15B, about 1004.2x DXR ($44.0M).
- Over the past year, DXR is up 15.5% and MDLN is down 17.6% - DXR leads by 33.1 points.
- MDLN has been more active in the news (20 items in the past 4 weeks vs 4 for DXR).
- MDLN has more recent analyst coverage (25 ratings vs 0 for DXR).
- Company
- Daxor Corporation
- Medline Inc.
- Price
- $9.78-9.07%
- $33.54-0.18%
- Market cap
- $44.0M
- $44.15B
- 1M return
- -5.28%
- -20.04%
- 1Y return
- +15.54%
- -17.57%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- AMEX
- NASDAQ
- IPO
- 2025
- News (4w)
- 4
- 20
- Recent ratings
- 0
- 25
Daxor Corporation
Daxor Corporation, a medical device company, provides biotechnology and cryobanking services in the United States. The company offers BVA-100 Blood Volume Analyzer, an instrument that measures blood volume in human body. BVA-100 Blood Volume Analyzer is used to diagnose and treat patients in various medical and surgical conditions, including congestive heart failure, critical care medicine and intensive care unit medicine, hypertension, syncope, pre-operative blood screening for hidden anemia, anemia in cancer patients, kidney failure, and hyponatremia. It also provides semen banking, blood storage, andrology, and general lab testing services. Daxor Corporation has a cooperative research and development agreement with the Uniformed Services University of the Health Sciences for researching the effectiveness of BVA-100 diagnostic test on quantifying circulatory blood volume in the context of traumatic injury. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was founded in 1970 and is headquartered in New York, New York.
Latest DXR
- SEC Form DEF 14A filed by Daxor Corporation
- Daxor Corporation Receives U.S. Patent for Breakthrough Remote Blood Volume Monitor
- SEC Form NT NPORT-P filed by Daxor Corporation
- Amendment: SEC Form 40-8F-2/A filed by Daxor Corporation
- SEC Form 40-17F2 filed by Daxor Corporation
- Daxor Leverages MedAxiom CV Transforum Spring'26 to Accelerate Commercial Adoption of Blood Volume Analysis
- SEC Form 4 filed by Feldschuh Michael Richard
- Daxor Expands Customer Footprint with New BVA Program at High-Volume Ohio Cardiology Center
- Amendment: SEC Form N-CEN/A filed by Daxor Corporation
- SEC Form 4 filed by Michel Robert J
Latest MDLN
- Medline Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Entry into a Material Definitive Agreement
- Large owner Hellman & Friedman Capital Partners X (Parallel), L.P. sold $1,164,385,709 worth of shares (31,868,237 units at $36.54) and disposed of 1,887,801 shares (SEC Form 4)
- Director Healy Patrick J acquired 202,106 shares, increasing direct ownership by 15% to 1,387,921 units (SEC Form 4)
- Large owner Bx Mozart Ml-2 Holdco L.P. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Large owner Bcp 8 Holdings Mozart Manager L.L.C. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Medline's Prime Vendor model expands outside the United States
- Medline Inc. announces closing of upsized secondary offering of Class A common stock
- Medline announces participation in upcoming investor conferences
- MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Large owner Bx Mozart Ml-1 Holdco L.P. converted options into 11,348,698 shares and disposed of 11,348,698 units of Class B Common Stock (SEC Form 4)